AZD2014 - mTOR Inhibitor. CAS# 1009298-59-2 0147 CUDC-907 was orally dosed to

CUDC-907 was orally dosed to mice at 100 mg/kg or intravenously dosed at 50 mg/kg once per day in the xenograft tumor model of SU-DHL4 (DLBCL) and A549 (NSCLC)

G-749 appears to be a promising next-generation drug candidate for the treatment of relapsed and refractory AML patients with various FLT3-ITD/FLT3-TKD mutants and further shows the ability to overcome drug resistance (Blood

especially the alpha-1 subunit

and it could effectively block both herpes simplex virus (HSV) and human cytomegalovirus (hCMV) infection via inhibition viral IE gene expression

Sharlow ER

AZD2014 - mTOR Inhibitor. CAS# 1009298-59-2 0147 CUDC-907 was orally dosed toAZD2014, CAS No. 1009298 59 2, is a highly potent, selective and ATP competitive mTOR inhibitor (IC50 = 2. 8 nM). It displays a high level of selectivity against other members of the PIKK family (IC50 against PI3K isoforms , , , = 3. 8 M, >30 M, >30 M and >29 M, respectively) and is inactive against a general panel of over 200 kinases when tested at 10 M. AZD2014 inhibits both mTORC1 and mTORC2 in vitro (pS6 (S235 236 ) IC50 = 0. 2 M, pAKT (S473) IC50